Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Chief Operating Officer | July 06, 2021 | July 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date July 06, 2021 · Filed July 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,790 |
Reported balance
After 2021-07-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-06 · Grant · Acquired 50,000 · Balance 124,790 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on July 6 of each year, with the first 1/2 vesting on July 6, 2022 and with the RSUs being fully vested on July 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. F2: Includes 122,083 RSUs and 1,388 shares of Common Stock purchased under Issuer's Employee Stock Purchase Plan on May 14, 2021 in a transaction exempt from Section 16(b) under Rule 16b3(c). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.63 · Expires 2031-07-06 | Direct | 150,000 |
Reported balance
After 2021-07-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-06 · Grant · Acquired 150,000 · Balance 150,000 F3: The underlying shares subject to the option vest and become exercisable as to 1/24th of the total number of shares subject to the option in successive, equal monthly installments measured from July 6, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on July 6 of each year, with the first 1/2 vesting on July 6, 2022 and with the RSUs being fully vested on July 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2: Includes 122,083 RSUs and 1,388 shares of Common Stock purchased under Issuer's Employee Stock Purchase Plan on May 14, 2021 in a transaction exempt from Section 16(b) under Rule 16b3(c).
F3: The underlying shares subject to the option vest and become exercisable as to 1/24th of the total number of shares subject to the option in successive, equal monthly installments measured from July 6, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2019 Filed Sep 18, 2019 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000899243-19-023816 · doc4.xml · derivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,488 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $20.03 | $50,075.00 |
DisclosureSEC source: 0000899243-19-023816 · doc4.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0000899243-19-023816 · doc4.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000899243-19-021944 · doc4.xml · derivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,988 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $19.00 | $47,500.00 |
DisclosureSEC source: 0000899243-19-021944 · doc4.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 20:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0000899243-19-021944 · doc4.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000899243-19-019764 · doc4.xml · derivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,488 Underlying: Common Stock · 2,500 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 2,500 | $19.20 | $48,000.00 |
DisclosureSEC source: 0000899243-19-019764 · doc4.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,310 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. F1 · balance_after: Includes 2,015 shares acquired on May 15, 2019, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Exercise / conversionCommon Stock, $0.0001 par value | 2,500 | $2.50 | $6,251.25 |
DisclosureSEC source: 0000899243-19-019764 · doc4.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,015 shares acquired on May 15, 2019, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0000899243-19-001201 · doc4.xml · derivative · entry 3 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2029-01-11 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | Tax withholdingCommon Stock, $0.0001 par value | 6,404 | $12.37 | $79,217.48 |
DisclosureSEC source: 0000899243-19-001201 · doc4.xml · nonDerivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,295 F1 · balance_after: Includes 1,552 shares acquired on November 15, 2018, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| January 11, 2019 Filed Jan 15, 2019 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 16,997 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-001201 · doc4.xml · nonDerivative · entry 1 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,699 F1 · balance_after: Includes 1,552 shares acquired on November 15, 2018, pursuant to Issuer's employee stock purchase plan. Read SEC document |
| May 14, 2018 Filed May 16, 2018 22:01 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0000899243-18-013087 · doc4.xml · derivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from May 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:09 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0000899243-18-006333 · doc4.xml · derivative · entry 2 Anicetti Vincent R · CIK 0001733375 · Chief, Quality & Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.